content_image/256235.jpg content_image/256236.jpg
## Oncology 

New drug XTANDI is driving strong growth in our oncology franchise toward GCL status. 

Astellas is focusing on establishing a Global Category Leader (GCL) position in the field of oncology after urology and transplantation. 

Our current oncology product lineup consists of XTANDI, Eligard and Gonax (all prostate cancer treatments) and Tarceva (for treatment of non-small cell lung cancer and pancreatic cancer). Aggregate sales of these four products saw sales in the oncology field soar 87% year on year in fiscal 2013 to ¥120.6 billion. 

XTANDI is a significant growth driver for us in the oncology field. It grew significantly with the U.S. net sales of US$441 million in fiscal 2013, an increase of 201% in year-on-year terms. XTANDI was launched in the U.K. in July 2013 and later in other EMEA markets. Net sales in EMEA in fiscal 2013 totaled € 71 million. In Japan, we launched XTANDI in May 2014 after gaining regulatory approval in March. The product is currently available in over 25 countries around the world. With the aim of maxi- mizing the value of XTANDI, we have filed applications in Europe and the U.S. for its approval for prostate cancer in chemotherapy-naïve patients. Clinical trials in earlier stage prostate cancer and breast cancer patients are also ongoing. 

Total Sales of XTANDI, Tarceva, Eligard and Gonax 

<img src='content_image/256235.jpg'>

In fiscal 2013, Tarceva-related revenues grew steadily, increasing 1.4% year on year on a U.S. dollar basis to US$446 million. In the U.S., Astellas is co-promoting Tarceva with Genentech, Inc., with earnings split equally. In regions outside the U.S., Astellas has a license agree- ment with F. Hoffmann-La Roche Ltd and receives  royalties based on sales. 

Eligard is currently marketed in EMEA, Asia & Oceania. Net sales in EMEA in fiscal 2013 declined 0.5% to € 139 million. Sales of Gonax, which was launched in Japan in October 2012, was ¥2.5 billion in fiscal 2013. 

As for new drug candidates, clinical trials are also ongoing for more than ten projects in the oncology field at present. 

## Oncology Pipeline 

<img src='content_image/256236.jpg'>

